RU2003122128A - METHOD OF COMBINED CUPPING OF DEPRESSIVE SYNDROMES OF SUBPSYCHOTIC LEVEL OF ENDOGENOUS GENESIS UNDER CONDITIONS OF THE DAY STAPIUM - Google Patents

METHOD OF COMBINED CUPPING OF DEPRESSIVE SYNDROMES OF SUBPSYCHOTIC LEVEL OF ENDOGENOUS GENESIS UNDER CONDITIONS OF THE DAY STAPIUM Download PDF

Info

Publication number
RU2003122128A
RU2003122128A RU2003122128/14A RU2003122128A RU2003122128A RU 2003122128 A RU2003122128 A RU 2003122128A RU 2003122128/14 A RU2003122128/14 A RU 2003122128/14A RU 2003122128 A RU2003122128 A RU 2003122128A RU 2003122128 A RU2003122128 A RU 2003122128A
Authority
RU
Russia
Prior art keywords
subpsychotic
endogenous
level
genesis
stapium
Prior art date
Application number
RU2003122128/14A
Other languages
Russian (ru)
Other versions
RU2249453C1 (en
Inventor
Игорь Викторович Боев (RU)
Игорь Викторович Боев
Ольга Альбертовна Ахвердова (RU)
Ольга Альбертовна Ахвердова
Владимир Алексеевич Якшин (RU)
Владимир Алексеевич Якшин
Виктор Владимирович Уваров (RU)
Виктор Владимирович Уваров
Олег Игоревич Боев (RU)
Олег Игоревич Боев
Original Assignee
Игорь Викторович Боев (RU)
Игорь Викторович Боев
Ставропольска государственна медицинска академи (RU)
Ставропольская государственная медицинская академия
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Игорь Викторович Боев (RU), Игорь Викторович Боев, Ставропольска государственна медицинска академи (RU), Ставропольская государственная медицинская академия filed Critical Игорь Викторович Боев (RU)
Priority to RU2003122128/14A priority Critical patent/RU2249453C1/en
Publication of RU2003122128A publication Critical patent/RU2003122128A/en
Application granted granted Critical
Publication of RU2249453C1 publication Critical patent/RU2249453C1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (1)

Способ комбинированного купирования депрессивных синдромов субпсихотического уровня эндогенного генеза в условиях дневного стационара, включающий в/в капельное введение трициклических антидепрессантов, отличающийся пероральным приемом селективных ингибиторов обратного захвата серотонина, в/в капельным введением 2,0-4,0 мл 1%-ного раствора амитриптилина на 200,0 мл физиологического раствора №12-14 при тревожном варианте депрессивного синдрома субпсихотического уровня эндогенного генеза, с сочетанием перорального приема золофта в дозе 50-100 мг и стратегической поддерживающей патогенетической терапией золофтом в дозе 100 мг в течение 3-х месяцев, а при апатическом варианте депрессивного синдрома субпсихотического уровня эндогенного генеза в/в капельным введением 2,0-4,0 мл 1, 25%-ного раствора мелипрамина на 200,0 мл физиологического раствора №12-14, с сочетанием перорального приема паксила в дозе 40-60 мг, и стратегической поддерживающей патогенетической терапией паксилом в дозе 40 мг в течение 3-х месяцев.A method for the combined relief of depressive syndromes of a subpsychotic level of endogenous genesis in an inpatient setting, including i.v. amitriptyline per 200.0 ml of physiological saline No. 12-14 with an alarming variant of depressive syndrome of subpsychotic level of endogenous genesis, with a combination of oral administration of zoloft in a dose of 50-1 00 mg and strategic supportive pathogenetic therapy with zoloft at a dose of 100 mg for 3 months, and with the apathetic variant of the depressive syndrome of subpsychotic level of endogenous genesis, IV drip 2.0-4.0 ml of a 25% solution of melipramine 200.0 ml of physiological saline No. 12-14, with a combination of oral administration of paxil in a dose of 40-60 mg, and strategic supportive pathogenetic therapy with paxil in a dose of 40 mg for 3 months.
RU2003122128/14A 2003-07-15 2003-07-15 Method for carrying out combined reduction of depressive syndromes of subpsychotic level and endogenous genesis in day care hospital RU2249453C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2003122128/14A RU2249453C1 (en) 2003-07-15 2003-07-15 Method for carrying out combined reduction of depressive syndromes of subpsychotic level and endogenous genesis in day care hospital

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2003122128/14A RU2249453C1 (en) 2003-07-15 2003-07-15 Method for carrying out combined reduction of depressive syndromes of subpsychotic level and endogenous genesis in day care hospital

Publications (2)

Publication Number Publication Date
RU2003122128A true RU2003122128A (en) 2005-02-27
RU2249453C1 RU2249453C1 (en) 2005-04-10

Family

ID=35285814

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003122128/14A RU2249453C1 (en) 2003-07-15 2003-07-15 Method for carrying out combined reduction of depressive syndromes of subpsychotic level and endogenous genesis in day care hospital

Country Status (1)

Country Link
RU (1) RU2249453C1 (en)

Also Published As

Publication number Publication date
RU2249453C1 (en) 2005-04-10

Similar Documents

Publication Publication Date Title
Tucker et al. From mitochondrial function to neuroprotection—an emerging role for methylene blue
Murali Doraiswamy Non-cholinergic strategies for treating and preventing Alzheimer’s disease
US8557867B2 (en) Inhibitors of NCCa-ATP channels for therapy
Hörl Iron therapy for renal anemia: how much needed, how much harmful?
RU2008127882A (en) TREATMENT OF THE ESOPHAGUS OF BARRETT
AR048318A1 (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
CR6834A (en) COMPLEXES AND COMPOSITIONS OF MACROMOLECULAR DRUGS CONTAINING THE SAME
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
Schwartz et al. Muehrcke's lines of the fingernails
DE60219963D1 (en) PHARMACEUTICAL COMPOSITION FOR THE CONTROL OF THE BLOOD SUGAR IN PATIENTS WITH TYPE 2 DIABETES
RU2003122128A (en) METHOD OF COMBINED CUPPING OF DEPRESSIVE SYNDROMES OF SUBPSYCHOTIC LEVEL OF ENDOGENOUS GENESIS UNDER CONDITIONS OF THE DAY STAPIUM
ES2403193T3 (en) Compositions comprising alprazolam for the treatment of primary insomnia and insomnia associated with anxiety states and procedures for their preparation
Qin et al. Transdermal application of azithromycin-amlodipine-heparin gel enhances survival of infected random ischaemic flap
ES2954768T3 (en) Composition comprising sterol derivatives for use in the treatment of a neuronal pathology associated with hypoxia, hypoglycemia and/or hyperglycemia
RU2002120894A (en) A method for the treatment of post-inflammatory bullous keratopathy
Kornowski et al. Ischemic stroke following an intramuscular injection of diclofenac: case report
Wagle et al. Pre-Emptive Analgesic Effect of Intravenous Paracetamol in Modified radical mastectomy
RU2206322C1 (en) Medicine agent eliciting analgetic and antipyretic effect
Kükürt et al. Understanding Vitamin C: Comprehensive Examination of Its Biological Significance and Antioxidant Properties
Leidmaa et al. Acute high-fat high-sugar diet rapidly increases blood-brain barrier permeability in mice
RU2002109173A (en) A method for the treatment of degenerative diseases of the retina
Lam et al. Generalised involuntary limb twitching after ingestion of Mesobuthus martensii Karsch (Quanxie) powder
RU2001118082A (en) METHOD FOR TREATING DISEASES OF THE VISUAL ANALYZER
RU2004107473A (en) METHOD FOR THERAPY OF CHRONIC OVERSTRAINING OF AN ATHLETES
DE602004016128D1 (en) USE OF SOLUBLE CD14 FOR THE TREATMENT OF DISEASES

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20100716

NF4A Reinstatement of patent

Effective date: 20120110

MM4A The patent is invalid due to non-payment of fees

Effective date: 20130716